Completion of Shareholdings Increase by CDC

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no 
responsibility for the contents of this announcement, make no representation as to its 
accuracy or completeness and expressly disclaim any liability whatsoever for any loss 
howsoever arising from or in reliance upon the whole or any part of the contents of this 
announcement.

 (a sino-foreign joint stock limited company incorporated in the People's Republic of China) 
                                       (Stock Code: 00991) 

                               OVERSEAS REGULATORY ANNOUNCEMENT
                             ANNOUNCEMENT ON COMPLETION OF A PLAN
                                 TO INCREASE SHAREHOLDINGS IN 
                        DATANG INTERNATIONAL POWER GENERATION CO., LTD 
                                  BY China Datang Corporation

Special Notice:

The board of directors (the "Board") and all directors (the "Directors") of the Company warrant 
that there are no false representations and misleading statements contained in, or material 
omissions from this announcement, and severally and jointly accept the responsibility for the 
truthfulness, accuracy and completeness of the content of this announcement. 

This announcement is made pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities 
on The Stock Exchange of Hong Kong Limited (the "Listing Rules"). 

Datang International Power Generation Co., Ltd. (the "Company") recently received a notice from 
China Datang Corporation ("CDC"), the controlling shareholder of the Company, confirmed the proceeding 
of a plan to increase its shareholding in the Company, by an amount not exceeding 2% of the total 
share capital of the Company, through the securities trading system of the Shanghai Stock Exchange 
since 6 May 2011. As at 4 May 2012, the amount of aggregated increased shareholdings of CDC accounted 
for 0.599% of the total issued share capital of the Company. CDC confirmed that such plan has been 
completed. The Company announces the details as follows:

I. Details of the increase in holding of shares

   On 6 May 2011, CDC increased its holding of the Company's A shares amounting to 2,335,501 A 
   shares through the securities trading system of the Shanghai Stock Exchange. CDC also intended to, 
   through itself or its subsidiaries to, continue to purchase A shares or H shares of the Company, 
   through the securities trading system of the Shanghai Stock Exchange or the Hong Kong market by 
   way of on-market or off-market transactions, within 12 months from 6 May 2011 according to their 
   own needs and the market situations. The aggregate amount of shares to be purchased shall not 
   exceed 2% of the total issued share capital of the Company (including the portion of increased 
   shares on 6 May 2011). CDC undertakes that CDC and its subsidiaries will not reduce their 
   respective shareholdings in the Company during the course of the share purchase plan and the 
   statutory period.

   On 4 May 2012, CDC confirmed that the share purchase plan has been completed. As at 4 May 2012, 
   CDC aggregately purchased 79,736,254 A shares of the Company since 6 May 2011 through the securities 
   trading system of the Shanghai Stock Exchange (excluding the 100,000,000 A shares subscribed by 
   CDC pursuant to an agreement entered into under the  non-public issue of A shares of the Company, 
   which was completed on 30 May 2011), representing 0.599% of the current total share capital of 
   the Company, which amounts to 13,310,037,578 shares. Upon the completion of the share purchase 
   plan, CDC directly held 4,138,977,414 A shares of the Company (including the non-public issue 
   of 100,000,000 A shares of the Company subscribed by CDC mentioned above), and indirectly held 
   480,680,000 H shares of the Company through China Datang Overseas (Hong Kong) Co., Limited, a 
   wholly-owned subsidiary of CDC, the aggregate of which represents approximately 34.71% of the 
   current total issued share capital of the Company. 

   CDC has abided by its undertaking and has not reduced its holding of shares in the Company in 
   the course of the share purchase plan.

II. Lawyer's Specific Opinion on Due Diligence Check

   Beijing Zhong Lun Law Firm has expressed its specific opinion on the due diligence check on the 
   increase in the shareholding in the Company by CDC: CDC has the capacity as a subject according 
   to law to increase its shareholding in the Company. Under paragraph 2(1) of Article 63 of the 
   "Measures Governing the Acquisition of Listed Companies", CDC is exempted from filing a waiver 
   application and can directly apply to the stock exchange and the securities registration and 
   clearing institution for processing the transfer of shares and registration of transfer. CDC 
   has executed the relevant approval procedures and the increase in shareholding complied with 
   the "Company Law of the People's Republic of China", the "Securities Law of the People's Republic 
   of China", the "Measures Governing the Acquisition of Listed Companies", "Guidelines for Shares 
   Purchase by Shareholders and Parties Acting in Concert of Listed Companies under the Shanghai 
   Stock Exchange" and relevant laws, regulations and other requirements under regulatory documents. 
   CDC has fulfilled the obligation of information disclosure and there was not any behavior of 
   contravention of laws and regulation during the course of the increase of shareholding.

                                                                                By Order of the Board  
                                                                                            Zhou Gang     
                                                                               Secretary to the Board 
Beijing, the PRC, 7 May 2012

As at the date of this announcement, the Directors of the Company are: 

Liu Shunda, Hu Shengmu, Cao Jingshan, Fang Qinghai, Zhou Gang, Liu Haixia, Guan Tiangang, Su Tiegang, 
Ye Yonghui, Li Gengsheng, Li Yanmeng*, Zhao Zunlian*, Li Hengyuan*, Zhao Jie*, Jiang Guohua*

* Independent non-executive Directors

END